|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NBPF19 |
Gene summary for NBPF19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NBPF19 | Gene ID | 101060226 |
| Gene name | NBPF member 19 | |
| Gene Alias | NBPF19 | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101060226 | NBPF19 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.59e-02 | 8.02e-01 | -0.1954 |
| 101060226 | NBPF19 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.35e-03 | -2.10e-01 | 0.3005 |
| 101060226 | NBPF19 | A002-C-010 | Human | Colorectum | FAP | 1.35e-02 | -1.68e-01 | 0.242 |
| 101060226 | NBPF19 | A015-C-203 | Human | Colorectum | FAP | 4.12e-09 | -9.54e-02 | -0.1294 |
| 101060226 | NBPF19 | A002-C-201 | Human | Colorectum | FAP | 6.32e-05 | -1.98e-01 | 0.0324 |
| 101060226 | NBPF19 | A001-C-108 | Human | Colorectum | FAP | 1.13e-04 | -1.21e-01 | -0.0272 |
| 101060226 | NBPF19 | A002-C-205 | Human | Colorectum | FAP | 3.93e-07 | -1.81e-01 | -0.1236 |
| 101060226 | NBPF19 | A015-C-006 | Human | Colorectum | FAP | 1.22e-03 | -2.18e-01 | -0.0994 |
| 101060226 | NBPF19 | A015-C-106 | Human | Colorectum | FAP | 2.80e-02 | -1.25e-01 | -0.0511 |
| 101060226 | NBPF19 | A002-C-114 | Human | Colorectum | FAP | 4.98e-04 | -7.56e-02 | -0.1561 |
| 101060226 | NBPF19 | A015-C-104 | Human | Colorectum | FAP | 4.11e-09 | -1.04e-01 | -0.1899 |
| 101060226 | NBPF19 | A001-C-014 | Human | Colorectum | FAP | 1.21e-02 | -3.86e-02 | 0.0135 |
| 101060226 | NBPF19 | A002-C-016 | Human | Colorectum | FAP | 4.35e-05 | -1.19e-01 | 0.0521 |
| 101060226 | NBPF19 | A015-C-002 | Human | Colorectum | FAP | 1.37e-03 | -2.25e-01 | -0.0763 |
| 101060226 | NBPF19 | A001-C-203 | Human | Colorectum | FAP | 4.92e-02 | -1.15e-01 | -0.0481 |
| 101060226 | NBPF19 | A002-C-116 | Human | Colorectum | FAP | 4.47e-10 | -2.36e-01 | -0.0452 |
| 101060226 | NBPF19 | A014-C-008 | Human | Colorectum | FAP | 7.16e-03 | -1.59e-01 | -0.191 |
| 101060226 | NBPF19 | A018-E-020 | Human | Colorectum | FAP | 5.35e-06 | -1.76e-01 | -0.2034 |
| 101060226 | NBPF19 | F034 | Human | Colorectum | FAP | 8.39e-05 | -1.27e-01 | -0.0665 |
| 101060226 | NBPF19 | F072B | Human | Colorectum | FAP | 1.47e-07 | -2.63e-01 | 0.257 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NBPF19 | SNV | Missense_Mutation | novel | c.8762N>C | p.Ile2921Thr | p.I2921T | A0A087WUL8 | protein_coding | tolerated(0.32) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| NBPF19 | SNV | Missense_Mutation | novel | c.1063G>A | p.Glu355Lys | p.E355K | A0A087WUL8 | protein_coding | tolerated(0.22) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| NBPF19 | insertion | Frame_Shift_Ins | novel | c.448_449insGATGTCTTTTTGA | p.Glu150GlyfsTer8 | p.E150Gfs*8 | A0A087WUL8 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| NBPF19 | SNV | Missense_Mutation | novel | c.11443T>G | p.Phe3815Val | p.F3815V | A0A087WUL8 | protein_coding | tolerated(0.07) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NBPF19 | SNV | Missense_Mutation | novel | c.5258N>G | p.Gln1753Arg | p.Q1753R | A0A087WUL8 | protein_coding | deleterious(0.04) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NBPF19 | SNV | Missense_Mutation | novel | c.407C>T | p.Pro136Leu | p.P136L | A0A087WUL8 | protein_coding | tolerated(0.61) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| NBPF19 | SNV | Missense_Mutation | novel | c.994C>T | p.Arg332Cys | p.R332C | A0A087WUL8 | protein_coding | deleterious(0.05) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NBPF19 | insertion | Frame_Shift_Ins | novel | c.11466_11467insT | p.Thr3825TyrfsTer25 | p.T3825Yfs*25 | A0A087WUL8 | protein_coding | TCGA-D5-6534-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NBPF19 | SNV | Missense_Mutation | novel | c.120N>T | p.Glu40Asp | p.E40D | A0A087WUL8 | protein_coding | tolerated(0.06) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| NBPF19 | SNV | Missense_Mutation | novel | c.748G>A | p.Glu250Lys | p.E250K | A0A087WUL8 | protein_coding | tolerated(0.16) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |